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Summary
Objective: Non-steroidal antiinflammatory agents are commonly used to treat pain and inflammation associated with osteoarthritis (OA), but
have poor gastrointestinal (GI) tolerability. This study compared the efficacy of the COX-2 specific inhibitor valdecoxib with naproxen and
placebo, in treating symptomatic OA of the hip.
Design: This multicenter, randomized, double-blind 12-week study compared the efficacy and tolerability of single daily doses of valdecoxib
5 mg and 10 mg with placebo or naproxen 500 mg BID. Efficacy was assessed by Patient’s and Physician’s Global Assessment of Arthritis,
and the WOMAC (Western Ontario and McMasters) OA Individual and Composite Indices. The incidence of adverse events was monitored
throughout the study.
Results: Valdecoxib was clinically and statistically superior to placebo for Patient’s and Physician’s Global Assessment of Arthritis and for all
WOMAC OA Indices over the 12 week study period (P≤0.05). Valdecoxib 10 mg was similar to naproxen in terms of efficacy, and
demonstrated greater numerical improvements compared with valdecoxib 5 mg. Valdecoxib 5 mg and 10 mg demonstrated similar
tolerability compared to placebo and a lower incidence of GI-related adverse effects compared with naproxen.
Conclusions: Single daily doses of valdecoxib 5 mg and 10 mg were similar to naproxen and superior to placebo, in treating symptomatic
OA of the hip. Both doses of valdecoxib were well tolerated and demonstrated improved GI tolerability compared to naproxen.
© 2002 Published by Elsevier Science Ltd on behalf of OsteoArthritis Research Society International
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COX-2 specific inhibitors, conventional non-steroidal anti-
inflammatory drugs (NSAIDs), and acetaminophen are
commonly used therapies for treatment of the pain and
functional impairment associated with osteoarthritis (OA) of
the hip. However, conventional NSAIDs are poorly toler-
ated by OA patients1 and their use can lead to potentially
life-threatening GI bleeding, perforations, and/or gastric
outlet obstruction2,3. Although acetaminophen is a front-
line therapy for the treatment of OA, patients receiving
acetaminophen have reported lower levels of satisfaction
compared with those receiving conventional NSAIDs, and
up to 30% have reported concurrent use of ibuprofen,
diclofenac or naproxen4. The recent introduction of COX-2
specific inhibitors for OA treatment has provided physicians
with an alternative therapy that has efficacy equivalent to
NSAIDs but with fewer side effects.
Conventional NSAIDs inhibit both isoforms of cyclo-
oxygenase (COX; COX-1 and COX-2), the enzyme that290converts arachidonic acid to prostaglandins5. COX-2
inhibition is responsible for the antiinflammatory and
analgesic effects of conventional NSAIDs and COX-2
specific inhibitors6. However, non-selective inhibition of
COX-1 by conventional NSAIDs, in addition to their inhib-
ition of COX-2, is thought to cause many of the undesirable
effects on the GI tract and on platelet function that are
typical of these agents5.
The COX-2 specific inhibitors, celecoxib and rofecoxib,
are as effective as conventional NSAIDs in treating OA7,8.
Additionally, these agents have improved GI tolerability at
therapeutic doses due to the lack of COX-1 inhibition9.
Valdecoxib is a novel, COX-2 specific inhibitor that is
approximately 28 000-fold more selective against COX-2
(hIC50=0.005 M) than COX-1 (hIC50=140 M)10. Val-
decoxib is being developed for the treatment of osteoarth-
ritis (OA) and rheumatoid arthritis (RA) and for the
management of pain.
Although commonly used to treat chronic pain and
inflammation associated with OA, conventional NSAIDs are
unacceptable to many patients because of poor GI toler-
ability, and increased risks of GI tract ulcers and ulcer
complications. As a COX-2 specific inhibitor, valdecoxib is
expected to effectively treat symptomatic OA while sparing
side effects associated with COX-1 inhibition. This random-
ized, placebo-controlled, 12-week study compared the effi-
cacy and tolerability of valdecoxib 5 mg QD and 10 mg QD
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PATIENTS
Patients with a diagnosis of symptomatic OA of the
hip11,12 were included in the study. Hip OA was defined as
hip pain plus at least two out of the following criteria:
Westergren erythrocyte sedimentation rate (ESR)<20 mm/
hour, radiographic femoral or acetabular osteophytes, or
radiographic joint space narrowing. These criteria are the
ACR definition of OA12. Eligible patients also had to have
had a baseline Patient’s Assessment of Arthritis Pain-VAS
score of ≥40 mm, and both Patient’s and Physician’s
Global Assessment of Arthritis of poor or very poor (see
below)13,14.
Patients with inflammatory arthritis, gout, pseudogout,
Paget’s disease or any chronic pain syndrome that inter-
fered with assessment of the Index Hip were excluded.
Patients with OA of the knee ipsilateral to the Index Hip,
symptomatic trochanteric bursitis or acute joint trauma of
the Index Hip were also excluded, as were patients
who had hip arthroscopy within the previous year, or had
complete loss of articular cartilage on weight-bearing X-ray
of the Index Hip. Patients with active GI disease, GI tract
ulceration within 30 days of study medication, or significant
bleeding disorder were also excluded.STUDY DESIGN
This multicenter, double-blind, randomized, placebo-
controlled, parallel group study compared the efficacy,
safety and tolerability of valdecoxib 5 mg QD and val-
decoxib 10 mg QD with naproxen 500 mg BID and placebo
over 12 weeks. The trial was conducted in 60 centers in
the United States and Canada, in accordance with the
principles of good clinical practice and the Declaration of
Helsinki. The study protocol was approved by Institutional
Review Boards for each treatment center.
Eligible patients were enrolled into the study and discon-
tinued regular pain medication at least 2 days before the
baseline assessment. Oxaprozin, piroxicam and full dose
aspirin (>325 mg/day) were discontinued at least 4 days
before the baseline arthritis assessment.EFFICACY ASSESSMENTS
Efficacy and safety assessments were made at out-
patient visits at baseline and 2, 6 and 12 weeks (or at
early termination) following administration of the first
dose of study medication. Patient’s Assessment of Arthritis
Pain-VAS was measured on a scale of 0–100 mm, where
0=no pain and 100=most severe pain. Patient’s Global
Assessment of Arthritis and Physician’s Global Assessment
of Arthritis were measured on a 5-point categorical scale;
1=very good, 2=good, 3=fair, 4=poor and 5=very poor.Prior to these assessments patients completed the
WOMAC OA index, a patient-administered questionnaire
consisting of 24 questions (five regarding pain, two regard-
ing stiffness and 17 regarding physical function) as
described previously15. The incidence of patient withdrawal
and time to patient withdrawal due to lack of study drug
efficacy were monitored.SAFETY ASSESSMENTS
General clinical safety was monitored by the incidence of
treatment-emergent adverse events, physical examination
including vital signs, and changes in clinical laboratory
variables. Adverse events were monitored at baseline and
throughout the study. Adverse events that occurred within
7 days of the last study medication dose and serious
adverse events that occurred within 30 days of the last
study dose were included in the safety analyses.STATISTICAL ANALYSIS
The sample size was calculated based on WOMAC OA
Pain Index scores and the primary comparison of each
dose of valdecoxib vs placebo. A sample size of 120
patients per treatment group was sufficient to detect a
mean change from baseline of >1.41 in the WOMAC OA
Pain Index score between treatment groups (valdecoxib
5 mg and 10 mg vs placebo) with at least 80% power and
type I error at 0.025 for a two-sided test corrected for
multiple comparisons.
Patient demographic/baseline data were compared
using the chi-squared test, except for the Patient’s and
Physician’s Global Assessments of Arthritis, which were
compared using the Cochran-Mantel-Haenszel (CMH) test
stratified by center.
Efficacy analyses were performed on a modified intent-
to-treat (ITT) cohort, which included all randomized
patients who took at least one dose of study medication.
The last observation carried forward (LOCF) method was
used to account for missing data. The LOCF method was
used to carry forward efficacy data that were missing at
weeks 2, 6 or 12, or were collected on assessment days
after the first dose of study medication in the following
intervals; >19 days for week 2, >49 days for week 6 and
>63 days for week 12. Mean change analyses were
performed on Patient’s Assessment of Arthritis Pain-VAS,
Patient’s and Physician’s Global Assessments of Arthritis,
all individual WOMAC OA Indices and the Composite
Index. Mean change analyses and overall and pairwise
comparisons for all four treatment groups were performed
using analysis of covariance (ANCOVA) with treatment and
center as factors and the corresponding baseline score as
a covariate. The results of the primary pairwise compari-
sons of valdecoxib 5 mg QD and 10 mg QD against
placebo for WOMAC OA Pain Index scores, Patient’s
Global Assessment of Arthritis and WOMAC OA Physical
Function Index scores were interpreted using Hochberg’s
step-down procedure16. The Patient’s and Physician’s
Global Assessments were categorized as improved,
unchanged or worsened and changes from baseline in
the categorical scale were analyzed using the CMH test,
stratified by center. The incidence of withdrawal due to
study drug failure was analyzed by Fisher’s exact test.
Incidence of adverse events and clinically significant
laboratory changes were compared using Fisher’s exactin relieving symptomatic OA of the hip, with placebo or
naproxen 500 mg BID, a conventional NSAID that repre-
sents the current standard of care. Efficacy was assessed
using Patient’s and Physician’s Global Assessments of
Arthritis, Patient’s Assessment of Arthritis Pain-visual
analog scale (VAS), and the Western Ontario and
McMasters (WOMAC) individual OA indices and
Composite index. The tolerability of the study medication
was assessed by the incidence of adverse events.
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ANCOVA, with treatment and center as factors and
Baseline scores as a covariate.ResultsPATIENTS
The disposition of patients is summarized in Fig. 1. A
total of 467 patients were randomized to receive study
medication and 209 withdrew before the end of the study
period. One patient was withdrawn prior to taking any
study medication and excluded from the ITT efficacy and
safety analyses. Patient baseline arthritis assessments,
demographics and other baseline characteristics were
comparable between all the treatment groups (Table I).EFFICACY OUTCOMES
Patients receiving either dose of valdecoxib or naproxen
experienced greater improvement in their OA symptoms at
each assessment compared with those receiving placebo.
Both doses of valdecoxib (5 mg QD and 10 mg QD) were
comparable to naproxen and significantly superior to
placebo (P≤0.05) for all OA assessments throughout the
study period (Tables II and III). The exception was the
Patient’s Assessment of Arthritis pain at the week 12
assessment where only valdecoxib 10 mg was statistically
significantly different from placebo (Table II). There were no
statistically significant differences between the WOMAC
scores for naproxen and valdecoxib 5 mg or 10 mg,
apart from the WOMAC Stiffness Index at week 2 in the
valdecoxib 5 mg group (P≤0.05) (Table III).
The incidence of withdrawal due to treatment failure in
response to both valdecoxib doses was significantly lower
than placebo (P≤0.05) and comparable to naproxen
500 mg BID. The incidence of withdrawal due to treatment
failure was 43.6% in the placebo, 26.7% in the valdecoxib
5 mg QD, 27.9% in the valdecoxib 10 mg QD and 20.3% inthe naproxen 500 mg BID treatment groups. Additionally,
patients in the placebo group withdrew at a significantly
faster rate than in any of the three active treatment
groups (P≤0.01), whereas all active treatment groups were
comparable to each other.SAFETY OUTCOMES
A higher number of patients in the naproxen 500 mg BID
treatment group (60.2%) reported treatment-emergent
adverse events compared with placebo (51.3%), val-
decoxib 5 mg QD (56.7%) and valdecoxib 10 mg QD
(51.3%) groups, although these differences were not
statistically significant (Table IV). There were no significant
differences in the incidence of adverse events between
either dose of valdecoxib and placebo. Most adverse
events were mild to moderate in severity, and less than
10% were severe in any treatment group.
The incidence of GI related adverse events was not
significantly different between either dose of valdecoxib
and placebo. In contrast, the rate of constipation in the
naproxen 500 mg BID was significantly higher than for the
valdecoxib 5 mg QD, valdecoxib 10 mg QD or placebo
groups (P≤0.05). Additionally, the rate of dyspepsia
was significantly higher in the naproxen 500 mg BID
group compared with valdecoxib 5 mg QD (P≤0.05) and
numerically higher than valdecoxib 10 mg QD.Fig. 1. Patient disposition: 467 patients were randomized to receive study medication and 209 withdrew prior to the end of the study.Discussion
This study confirmed that valdecoxib was as effective as
the conventional NSAID naproxen in treating symptomatic
OA of the hip. Single daily doses of valdecoxib 5 mg and
10 mg provided sustained efficacy over 12 weeks that was
clinically and statistically better than placebo and similar to
naproxen 500 mg BID in treating symptomatic OA of the
hip. Moreover, valdecoxib demonstrated improved GI toler-
ability compared with naproxen. Although both doses of
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Patient baseline characteristics (QD=once daily, BID=twice daily)
Placebo
(N=118)
Valdecoxib
5 mg QD
(N=120)
Valdecoxib
10 mg QD
(N=111)
Naproxen
500 mg BID
(N=118)
P-value
Mean age (yrs) (mean±S.D.) 62.1±11.9 60.4±11.6 63.9±12.1 63.1±11.4 0.23
Mean weight (kg) (mean±S.D.) 81.6±20.3 86.1±21.6 83.6±19.4 81.3±18.5 0.35
Race N (%)
Caucasian 113 (96%) 113 (94%) 105 (95%) 111 (94%) 0.95
Black 3 (3%) 6 (5%) 5 (5%) 5 (4%)
Hispanic 2 (2%) 1 (1%) 1 (1%) 2 (2%)
Gender N (% males) 37 (31%) 39 (33%) 38 (34%) 37 (31%) 0.96
Disease duration (yrs) (mean±S.D.) 6.2±6.8 6.4±7.4 6.5±6.5 5.3±5.9 0.42
History of GI bleeding N (%)
Yes 1 (1%) 1 (1%) 0 (0%) 4 (3%) 0.12
No 117 (99%) 119 (99%) 111 (100%) 114 (97%)
Gastroduodenal ulcer N (%)
Yes 13 (11%) 10 (8%) 14 (13%) 11 (9%) 0.72
No 105 (89%) 110 (92%) 97 (87%) 107 (91%)
Patient’s Global Assessment of Arthritis N (%)
Fair 1 (1%) 0 (0%) 1 (1%) 1 (1%) 0.49
Poor 97 (82%) 105 (88%) 95 (86%) 108 (92%)
Very poor 19 (16%) 15 (13%) 15 (14%) 9 (8%)
Physician’s Global Assessment of Arthritis N (%)
Fair 2 (2%) 0 (0%) 1 (1%) 1 (1%) 0.75
Poor 100 (85%) 109 (91%) 101 (91%) 108 (92%)
Very poor 16 (14%) 11 (9%) 9 (8%) 9 (8%)
Patient’s Assessment of Arthritis Pain-VAS (Mean±S.D.) 71.3±15.2 72.3±15.1 73.4±14.4 69.0±15.4 0.15
Baseline WOMAC OA Index (Mean±S.D.)
Pain 10.8±3.1 11.2±3.2 10.8±3.1 10.5±3.2 0.43
Stiffness 4.6±1.5 5.0±1.5 4.8±1.4 4.7±1.5 0.38
Physical function 37.1±11.0 38.6±11.3 37.0±10.1 36.6±10.4 0.42
Composite 52.6±14.3 54.7±15.2 52.8±13.5 51.8±13.9 0.37Table II
Mean least squares change from baseline for Patient’s Global Assessment of Arthritis, Physician’s Global
Assessment of Arthritis and Patient’s Assessment of Arthritis Pain
Placebo
(N=117)
Valdecoxib
5 mg QD
(N=120)
Valdecoxib
10 mg QD
(N=111)
Naproxen
500 mg BID
(N=118)
Patient’s Global Assessment of Arthritis‡
Baseline mean 4.1 4.1 4.1 4.1
LS mean change
Week 2 −0.72 −1.10**† −1.26***† −1.31***
Week 6 −0.82 −1.11*† −1.29***† −1.30***
Week 12 −0.87 −1.20*† −1.29**† −1.18*
Physician’s Global Assessment of Arthritis‡
Baseline mean 4.1 4.1 4.1 4.1
LS mean change
Week 2 −0.72 −1.10**† −1.22***† −1.32***
Week 6 −0.84 −1.17*† −1.25**† −1.28***
Week 12 −0.88 −1.18* −1.25* −1.23*
Patient’s Assessment of Arthritis Pain§
Baseline mean 71.2 72.3 73.4 69.0
LS mean change
Week 2 −14.4 −21.0* −24.6** −27.3***
Week 6 −16.0 −23.3* −25.8** −26.1**
Week 12 −15.2 −21.3 −23.2* −22.0
Statistically significant *P≤0.05 vs placebo, **P≤0.01 vs placebo, ***P<0.001 vs placebo.
†Statistically significantly different from placebo in pairwise comparisons.
‡Scale ranged from 1 (very good) to 5 (very poor).
§Scale ranged from 0–100 mm, with 0=no pain and 100=most severe pain.valdecoxib were comparable in efficacy to naproxen
500 mg BID, valdecoxib 10 mg demonstrated consistently
better numerical improvements than valdecoxib 5 mg inPatient’s and Physician’s Assessments of arthritis, in the
WOMAC OA Indices, and in Patient’s Assessment of
Pain-VAS. The efficacy of valdecoxib 10 mg in treating
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Mean Least Squares Change from Baseline WOMAC Osteoarthritis Index Pain, Physical Function, and Stiffness
Indices and Composite Index
Placebo
(N=117)
Valdecoxib
5 mg QD
(N=120)
Valdecoxib
10 mg QD
(N=111)
Naproxen
500 mg BID
(N=118)
Pain Index§
Baseline mean 10.8 11.2 10.8 10.5
LS mean change
Week 2 −0.90 −2.48***‡ −2.56***‡ −3.07***
Week 6 −1.09 −2.76***‡ −3.23***‡ −3.14***
Week 12 −1.25 −2.54*‡ −2.83**‡ −2.94**
Physical Function Index\
Baseline mean 37.1 38.6 37.0 36.6
LS mean change
Week 2 −2.84 −7.50**‡ −9.01***‡ −10.1***
Week 6 −3.17 −8.44***‡ −10.2***‡ −10.4***
Week 12 −3.18 −8.20**‡ −10.0***‡ −9.63***
Stiffness Index¶
Baseline mean 4.6 5.0 4.8 4.7
LS mean change
Week 2 −0.34 −0.82*† −1.14*** −1.25***
Week 6 −0.57 −1.07* −1.24** −1.22**
Week 12 −0.60 −1.09* −1.19** −1.21**
Composite Index††
Baseline mean 52.6 54.7 52.8 51.8
LS mean change
Week 2 −4.31 −10.8** −12.6*** −14.3***
Week 6 −5.07 −12.3** −14.7*** −14.7***
Week 12 −5.28 −12.0** −14.0*** −13.8***
Statistically significant *P≤0.05 vs placebo, **P≤0.01 vs placebo, ***P<0.001 vs placebo.
†P≤0.05 vs naproxen.
‡Statistically significantly different from placebo in pairwise comparisons according to Hochberg’s procedure.
§Scale ranged from 0 to 20, with lower score as better.
\Scale ranged from 0 to 68, with lower score as better.
¶Scale ranged from 0 to 8, with lower score as better.
††Scale ranged from 0 to 96, with lower score as better.symptomatic OA of the hip, demonstrated in this study, is
consistent with an earlier dose ranging study that demon-
strated daily doses of valdecoxib of 10 mg and 20 mg to be
efficacious in treating OA of the knee17. Data presented
here confirm that a daily dose of valdecoxib of 10 mg can
be as effective as naproxen and is, therefore, an effective
dose for treating pain and inflammation associated with
OA.
COX-2 and prostaglandin levels are elevated in inflamed
tissue of OA-affected joints, and in nociceptive sensory
neurons in the spinal cord in response to inflammation and
tissue damage6,18,19. The data from this study are consist-
ent with selective inhibition of COX-2 activity and prosta-
glandin production, at therapeutic doses of valdecoxib,
in damaged joints and in the CNS, thereby reducing
inflammation and peripheral and central sensitization to
pain in OA patients. Furthermore, effective treatment of
symptomatic OA requires agents that have a long duration
of action and a good GI safety profile as well as being
powerful analgesics.
Valdecoxib once a day was associated with a long
duration of action that was comparable to naproxen admin-
istered BID and significantly better than placebo, as
demonstrated by the significantly faster rate of withdrawal
due to treatment failure from the placebo group. This long
duration of action for valdecoxib is important for effective
treatment of chronic pain associated with inflammatory
diseases. The efficacy and duration of action of valdecoxib
is also consistent with published reports demonstratingthat other COX-2 specific inhibitors are as effective as
conventional NSAIDs in improving the symptoms of OA7,8.
Conventional NSAID therapy is associated with serious
GI complaints such as ulceration, perforation and GI bleed-
ing, and with low GI tolerability manifested as symptoms
such as dyspepsia, nausea, vomiting, diarrhea/or consti-
pation, and abdominal pain20,21. The relative COX-1 spar-
ing nature of COX-2 specific inhibitors means that they
have an improved GI and platelet safety profile compared
with conventional NSAIDs9. In this study valdecoxib (5 mg
and 10 mg) was well tolerated, with an adverse event
profile similar to placebo and GI tolerability that was better
than that observed for naproxen. Gastrointestinal-related
adverse effects such as dyspepsia, constipation, abdomi-
nal pain, and nausea were considerably more common
among patients who received naproxen compared to either
dose of valdecoxib. The low GI tolerability of conventional
NSAIDs often leads to poor compliance and/or discontinu-
ation of medication, particularly among patients who suffer
from OA and RA and who require long-term treatment for
chronic pain and inflammation9. Thus, agents such as
valdecoxib, which provide similar efficacy and improved GI
safety and tolerability compared to conventional NSAIDs,
will prove invaluable in treating arthritis patients.
Overall, this study suggests significant clinical benefits
for single daily doses of valdecoxib in treating symptomatic
OA of the hip. The enhanced efficacy of valdecoxib 10 mg
compared to 5 mg, suggests that 10 mg is an appropriate
daily dose for the treatment of OA. At this dose, the efficacy
Osteoarthritis and Cartilage Vol. 10, No. 4 295of valdecoxib is comparable to naproxen 500 mg BID, but
has the advantage of a better GI tolerability profile than that
associated with naproxen.Table IV
Incidence of adverse events
Placebo
(N=117)
N (%)
Valdecoxib
5 mg QD
(N=120)
N (%)
Valdecoxib
10 mg QD
(N=111)
N (%)
Naproxen
500 mg BID
(N=118)
N (%)
Adverse events with incidence ≥5% in any treatment group
Total 60 (51.3) 68 (56.7) 57 (51.3) 71 (60.2)
Accidental injury 2 (1.7) 6 (5.0) 4 (3.6) 4 (3.4)
Headache 14 (12.0) 8 (6.7) 4 (3.6)* 4 (3.4)*
Abdominal pain 5 (4.3) 8 (6.7) 5 (4.5) 12 (10.2)
Constipation 1 (0.9) 1 (0.8)† 0 (0.0)† 8 (6.8)*
Diarrhea 2 (1.7) 6 (5.0) 5 (4.5) 6 (5.1)
Dyspepsia 6 (5.1) 3 (2.5)† 4 (3.6) 11 (9.3)
Nausea 4 (3.4) 5 (4.2) 5 (4.5) 10 (8.5)
Sinusitis 3 (2.6) 7 (5.8) 1 (0.9) 2 (1.7)
Upper respiratory tract infections 6 (5.1) 4 (3.3) 7 (6.3) 3 (2.5)
GI-related adverse events causing withdrawal
Total GI tract disorders 2 (1.7) 5 (4.2) 5 (4.5) 13 (11.0)*
Abdominal pain 0 (0.0) 1 (0.8)† 2 (1.8) 8 (6.8)*
Constipation 0 (0.0) 0 (0.0) 0 (0.0) 2 (1.7)
Diarrhea 1 (0.9) 0 (0.0) 2 (1.8) 3 (2.5)
Diverticulitis 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
Dyspepsia 1 (0.9) 0 (0.0) 2 (1.8) 3 (2.5)
Flatulence 0 (0.0) 1 (0.8) 1 (0.9) 1 (0.8)
Gastroesophageal reflux 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.8)
Nausea 0 (0.0) 2 (1.7) 1 (0.9) 2 (1.7)
Hemorrhoids bleeding 0 (0.0) 1 (0.8) 0 (0.0) 0 (0.0)
*P≤0.05 vs placebo, †P≤0.05 vs naproxen.References
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